Profile: CDR Therapeutics Inc. develops drug for therapeutic applications in the treatment of cancer, autoimmune diseases, transplant rejection, eye injury and skin diseases. We focus on the development of small molecules that mimic the active component of monoclonal antibodies, which are utilized for a variety of therapeutic applications. These small molecules, which represent a new class of drugs, have the potential to be more efficacious, less toxic, and less expensive to manufacture than antibodies. We also concentrate in the areas of dermatology & ophthalmology and maintain rights to therapeutic applications in oncology and immunology. We develop a new class of products that combines specific monoclonal antibodies with pharmaceutical properties of small molecule-based drugs. We focus on the clinical development of its lead compounds for therapeutic applications in oncology, dermatology and ophthalmology. One lead anti-cancer compound has been demonstrated to bind to an oncogene product and suppresses the growth of a variety of tumors in laboratory tests and in animal models. A second lead compound is a potent immunosuppressive agent that blocks the activation of lymphocytes and has been demonstrated to inhibit inflammatory responses in animal models. This compound initially will be pursued as a topical agent for the treatment of the common inflammatory skin disorder called psoriasis. Another lead compound stimulates the growth of epithelial cells found in the cornea of the eye. This compound is developed as topical eye drops for corneal injury or surgery.